PART I Overview We are a clinical stage biotherapeutics company focusing on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. We are advancing a portfolio of oral therapeutics using our proprietary delivery technology and we are actively pursuing partnering the technology with third party biopharmaceutical companies for the oral delivery of their biologics...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001193125-26-126417 | EDGAR | 108K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-047740 | EDGAR | — |
| 2024-03-20 | 2023-12-31 | 0000950170-24-034163 | EDGAR | — |
| 2023-03-22 | 2022-12-31 | 0000950170-23-009178 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0000950170-22-005088 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269774 | EDGAR | 27K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105045 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070382 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-126763 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091793 | EDGAR | — |
| 2024-05-06 | 2024-03-31 | 0000950170-24-053548 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061137 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041852 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0000950170-23-020554 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024442 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0000950170-22-016492 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0000950170-22-009334 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-04 | 0001193125-26-331594 | EDGAR | — |
| 2026-03-26 | 0001193125-26-126240 | EDGAR | 3K words |
| 2026-01-02 | 0001193125-26-001098 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269722 | EDGAR | — |
| 2025-10-27 | 0001193125-25-250614 | EDGAR | — |
| 2025-10-17 | 0001193125-25-241963 | EDGAR | — |
| 2025-08-07 | 0000950170-25-104998 | EDGAR | — |
| 2025-07-16 | 0001193125-25-159793 | EDGAR | — |
| 2025-06-26 | 0000950170-25-090384 | EDGAR | — |
| 2025-05-29 | 0000950170-25-078949 | EDGAR | — |
97 total filings indexed. 70 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001856725 |
| Ticker | RANI |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | CA |
| Website | https://www.ranitherapeutics.com |
| Listed | 2021-07-30 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/RANI (~200 tokens, structured JSON with cryptographic provenance)